Immunogenicity and safety of Mycobacterium tuberculosis culture filtrate proteins non-human primates

Clinical and Experimental Immunology

Volumn 119, Issue 1, 2000, Pages 84-91

  Attanasio, R ^a   Pehler, K ^a   McClure, H M ^a,b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Rhesus macaques; Secreted antigens; Tuberculosis; Vaccines

Indexed keywords

BACTERIAL PROTEIN; BCG VACCINE; GAMMA INTERFERON; TUBERCULOSIS PROTEIN VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; DRUG SAFETY; FEMALE; IMMUNOGENICITY; IMMUNOMODULATION; MACACA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS CONTROL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAMUSCULAR; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MACACA MULATTA; MYCOBACTERIUM TUBERCULOSIS; SAFETY; TUBERCULOSIS;

EID: 0033977787     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01075.x     Document Type: Article

References (31)

1. 1 Sudre P, ten Dam G, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Organ 1992; 70:149-59.
2. 2 Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72:213-20.
3. 3 Colditz GA, Brewer TF, Berkeley CS et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta analysis of the published literature. JAMA 1994; 271:698-702.
4. 4 Styblo K, Meiger J. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 1976; 57:17-43.
5. 5 Jacobs GG, Johnson JL, Boom WH et al. Tuberculosis vaccines: how close to human testing? Tuberc Lung Dis 1997; 78:159-69.
6. 6 Sonnenberg MG, Belisle JT. Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. Infect Immun 1997; 65:4515-24.
7. 7 Andersen P. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1997; 62:2536-44.
8. 8 Horwitz MA, Lee B-Y, Dillon BJ, Harth G. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1995; 92: 1530-4.
9. 9 Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med 1996; 2:888-92.
10. 10 Huygen K, Content J, Denis O et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 2:893-8.
11. 11 Ellner JJ. Review: the immune response in human tuberculosis-implications for tuberculosis control. J Infect Dis 1997; 176:1351-9.
12. 12 Roberts AD, Sonnenberg MG, Ordway DJ, Furney SK, Brennan PJ, Belisle JT, Orme IM. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 1995; 85:502-8.
13. 13 Ansari AA, Brodie AR, Fultz PN, Anderson DC, Sell KW, McClure HM. Flow microfluorometric analysis of peripheral blood mononuclear cells from nonhuman primates; correlation of phenotype with immune function. Am J Primatol 1989; 17:107-31.
14. 14 Attanasio R, Pehler K, Scinicariello F. DNA-based immunization induces anti-CD4 antibodies directed primarily to native epitopes. FEMS Immunol Med Microbiol 1997; 17:207-15.
15. 15 Centers for Disease Control and Prevention. Development of new vaccines for tuberculosis: recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR 1998; 47:1-6.
16. 16 Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998; 11:514-32.
17. 17 Teitelbaum R, Glatman-Freedman A, Chen B et al. A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci USA 1998; 95:15688-93.
18. 18 Baldwin SL, D' Souza C, Roberts AD et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 1998; 66:2951-9.
19. 19 Havlir DV, Wallis RS, Boom WH, Daniel TM, Chervenak K, Ellner JJ. Human immune response to Mycobacterium tuberculosis antigens. Infect Immun 1991; 59:665-70.
20. 20 Daugelat S, Gulle H, Schoel B, Kaufmann SHE. Secreted antigens of Mycobacterium tuberculosis: characterization with T lymphocytes from patients and contacts after two-dimensional separation. J Infect Dis 1992; 166:186-90.
21. 21 Ohmen JD, Bames PF, Grisso CL, Bloom BR, Modlin RL. Evidence for a superantigen in human tuberculosis. Immunity 1994; 1:35-43.
22. 22 van Eden W, Hogervorst EJM, Hensen EJ, van der Zee R, van Embden JDA, Cohen IR. A cartilage-mimicking T-cell epitope on a 65K mycobacterial heat-shock protein: adjuvant arthritis as a model for human rheumatoid arthritis. Curr Top Microbiol Immunol 1989; 145:27-43.
23. 23 Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-45.
24. 24 Lozes E, Denis O, Drowart A et al. Cross-reactive immune responses against Mycobacterium bovis BCG in mice infected with non-tuberculous mycobacteria belonging to the MAIS-group. Scand J Immunol 1997; 46:16-26.
25. 25 Fine PEM, Vynnycky E. The effect of heterologous immunity upon the apparent efficacy (e.g. BCG) vaccines. Vaccine 1998; 16:1923-7.
26. 26 Grange JM. The humoral immune response in tuberculosis: its nature, biological role and diagnostic usefulness. Adv Tuberc Res 1984; 21:1-78.
27. 27 Daniel T, Debanne SM. The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay. Am Rev Respir Dis 1987; 135:662-5.
28. 28 Comstock GW. Field trials of tuberculosis vaccines: how could we have done them better? Control Clin Trials 1994; 15:247-76.
29. 29 Harboe M, Nagai S, Patarroyo ME, Torres ML, Ramirez C, Cruz N. Properties of proteins MBP64, MBP70, and MBP80 of Mycobacterium bovis BCG. Infect Immun 1986; 52:293-302.
30. 30 McClure HM. Bacterial diseases of nonhuman primates. In: Montali RJ, Migaki G, eds. The comparative pathology of zoo animals. Washington, DC: Smithsonian Institution Press, 1980:197-204.
31. 31 Kaufmann SHE. Immunity to intracellular bacteria. In: Paul WE, eds. Fundamental immunology. Philadelphia: Lippincott-Raven Publishers, 1998:1335-71.